Cure My Disease

Don't miss your cure!

 Log in / Sign up

Inhaled experimental drug targets tough lung infections

NCT ID NCT07709494

Not yet recruiting Disease control Sponsor: Revagenix, Inc. Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This early-stage trial tests an inhaled drug called Rev-56 in healthy volunteers and in people with non-cystic fibrosis bronchiectasis who have chronic Pseudomonas aeruginosa lung infections. The study checks whether the drug is safe and how the body processes it, comparing Rev-56 to a placebo. If it passes safety checks, it may offer a new way to control these stubborn infections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an inhaled experimental drug called Rev-56
What this could lead to
If successful, this could lead to a new inhaled treatment for chronic Pseudomonas infections in people with bronchiectasis.
What could go wrong
This is an early Phase 1 trial focused on safety, so it is too soon to know if Rev-56 will effectively treat infections. Side effects or lack of benefit may emerge.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bronchiectasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY PARTICIPANTS NON-CYSTIC FIBROSIS BRONCHIECTASIS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Syneos Health Miami

    Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.